Impact of Premedication on Anxiety

Preoperative Anxiety Clinical Trial

— Impact  

Official title:

Impact of Premedication on Anxiety: a Multi-centre, Prospective Observational Cohort Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04103723
• Other study ID #: 19-132
• Status: Recruiting
• Start date: October 7, 2019
• Est. completion date: September 30, 2021

Study information

• Verified date: October 2020
• Source: RWTH Aachen University
• Contact: Ana Kowark née Stevanovic, MD
• Phone: +49241-8088179
• Email: anaesthesiologie[@]ukaachen.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

IMPACT aims to evaluate the clinical routine practice of premedication in German hospitals and to estimate the influence of premedication on anxiety reduction.

Description:

Generalised premedication with benzodiazepines in all surgical patients has become questionable, regarding the risk-benefit assessment and the lack of evidence for this practice. One of the main justifications for premedication with benzodiazepines is its anxiolytic effect. Anxiety is associated with postoperative cognitive and behavioural changes, physiological reactions, increased need of anaesthetic drugs and altered perception of pain, mood swings, wound-healing problems and alteration of the immune system. However, several investigations revealed negative side-effects like dose-dependent sedation up to respiratory depression, prolonged extubation-time, impaired psychomotor function, paradox reactions, antegrade amnesia, increased pneumonia rates and postoperative delirium.

In Germany midazolam is the most frequently administered premedication. A survey revealed that about one third of the German hospitals withhold a premedication in patients older than 74 years.

The evidence for this practice, as well as the indiscriminate preoperative premedication for all adult patients is low.

The investigators aim to recruit as many as possible centers throughout Germany, to participate in this study. A total sample size of 4000 patients will provide reasonable and valid results for the study aims. The influence of premedication on the primary endpoint change of APAIS-score will be analysed by a multivariable analysis of covariance considering several baseline characteristics. In case of significant interaction terms, subgroup analysis will be performed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 4000
• Est. completion date: September 30, 2021
• Est. primary completion date: August 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Only legally competent patients

• Written informed consent prior to study participation

• Age =18 years, both genders

• Elective surgery

• Expected surgery duration = 30 minutes

• Planned general or combined regional and general anaesthesia

• Planned extubation (or removal of airway device) at the end of surgery

Exclusion Criteria:

• Age <18 years

• Non-fluency in German language

• Alcohol and/ or drug abuse

• Chronic benzodiazepine treatment

• Intracranial surgery

• Local or solely regional anaesthesia

• Monitored anaesthesia care/ Sedation

• Cardiac surgery

• Ambulatory surgery

• Repeated surgery with previous participation in the trial

• Expected continuous mandatory ventilation after surgery

• Patients with severe neurological or psychiatric disorders

• Refusal of study participation by the patient

Related Conditions & MeSH terms

• Anxiety Disorders
• Preoperative Anxiety

Intervention

Procedure:
• Preoperative premedication
Every patient with or without a preoperative premedication with midazolam before surgery.

Locations

Country	Name	City	State
Germany	University Hospital RWTH Aachen	Aachen	NRW

Sponsors (1)

Lead Sponsor	Collaborator
RWTH Aachen University

Country where clinical trial is conducted

Germany, 

References & Publications (2)

Bauer M, Böhrer H, Aichele G, Bach A, Martin E. Measuring patient satisfaction with anaesthesia: perioperative questionnaire versus standardised face-to-face interview. Acta Anaesthesiol Scand. 2001 Jan;45(1):65-72. — View Citation

https://euroqol.org/wp-content/uploads/2016/09/EQ-5D-3L_UserGuide_2015.pdf

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of the preoperative anxiety level	Change of the preoperative anxiety level, measured with the anxiety measuring scale, named: "Amsterdam Preoperative Anxiety and Information Scale (APAIS)". The measure of agreement with six statements is graded on a 5-point Likert scale from 1 "not at all" to 5 "extremely." A score of =11 identify anxious patients in clinical practice. Assessed at: pre-interventional at baseline visit (visit 0) and pre-interventional before surgery (visit 1).	Up to 30 days
Secondary	Change in systolic blood pressure	Difference in the haemodynamic variable systolic blood pressure (measured in mmHg) between the assessment pre-interventional at baseline visit (visit 0) and the pre-interventional visit right before surgery (visit 1) and directly post-interventional in the recovery room at visit 2.	Up to 31 day
Secondary	Change in diastolic blood pressure	Difference in the haemodynamic variable diastolic blood pressure (measured in mmHg) between the assessment pre-interventional at baseline visit (visit 0) and the pre-interventional visit right before surgery (visit 1) and directly post-interventional in the recovery room at visit 2.	Up to 31 day
Secondary	Change in heart rate	Difference in haemodynamic variable (heart rate) between patients with and without premedication. The assessment is conducted pre-interventional at baseline visit (visit 0), in the pre-interventional visit right before surgery (visit 1) and directly post-interventional in the recovery room at visit 2. The values are presented as beats per minute.	Up to 31 day
Secondary	Change in oxygen saturation	Difference in the respiratory variable (oxygen saturation) between patients with and without premedication. The assessment is conducted pre-interventional at baseline visit (visit 0), in the pre-interventional visit right before surgery (visit 1) and directly post-interventional in the recovery room at visit 2. The values are presented in percent.	Up to 31 day
Secondary	Difference in the cognitive function at baseline as part of the baseline frailty assessment	Cognitive function will be assessed at baseline as part of the frailty assessment according to Oresanya, among the patients who received a premedication and patients without premedication. It will be assessed by the Mini-Cog test, which is a 3-minute instrument that can increase detection of cognitive impairment. It consists of two components, a 3-item recall test for memory and a simply scored clock drawing test.; Scale: word recall: 0-3 points; Clock Draw: 0 or 2 points; Total Score: 0-5 points	1 day
Secondary	Difference in the medical history at baseline as part of the baseline frailty assessment	Medical history will be assessed at baseline and used for the combined frailty assessment according to Oresanya. Patients will be scored as frail, if = 3 comorbidities are present of the Charlson Comorbidity Index.	1 day
Secondary	Difference in the laboratory value albumin at baseline as part of the baseline frailty assessment	Laboratory value Albumin (unit: g/dl or g/l, depending on the hospital routine), will be assessed according to the clinical routine of the centres. This assessment is optional. It will occur at baseline and will be used for the combined frailty assessment according to Oresanya.	1 day
Secondary	Difference in the laboratory value creatinine at baseline as part of the baseline frailty assessment	Laboratory value Creatinine (unit:mg/dl or µmol/l, depending on the hospital routine), will be assessed according to the clinical routine of the centres. This assessment is optional. It will occur at baseline and will be used for the combined frailty assessment according to Oresanya.	1 day
Secondary	Difference in the laboratory value haemoglobin at baseline as part of the baseline frailty assessment	Laboratory value Creatinine (unit: g/dl or mmol/l, depending on the hospital routine), will be assessed according to the clinical routine of the centres. This assessment is optional. It will occur at baseline and will be used for the combined frailty assessment according to Oresanya.	1 day
Secondary	Difference in the laboratory value haematocrit at baseline as part of the baseline frailty assessment	Laboratory value haematocrit (unit: l/l or %, depending on the hospital routine), will be assessed according to the clinical routine of the centres. This assessment is optional. It will occur at baseline and will be used for the combined frailty assessment according to Oresanya.	1 day
Secondary	Difference in history of falls at baseline as part of baseline frailty assessment	History of falls in the previous 6 months will be assessed at baseline as part of the combined frailty assessment according to Oresanya, among the patients who received a premedication and patients without premedication. Patients will be asked, whether the had one fall, more than one fall, or no fall in the previous 6 months. Patients with more than 1 fall in the last 6 months, has to be marked as "frailty" criterion present according to Oresanya.	1 day
Secondary	Difference in the mobility of the patients as part of baseline frailty assessment	The timed "Up & Go" test, will be used to assess the mobility of the patients at baseline, as part of the frailty assessment according to Oresanya, among the patients who received a premedication and patients without premedication. It uses the time that a person takes to rise from a chair, walk three meters, turn around, walk back to the chair, and sit down.	1 day
Secondary	Unintentional weight loss at baseline as part of baseline frailty assessment	Unintentional weight loss will be assessed at baseline as part of the frailty assessment. Patients will be asked if they have lost >4,5kg weight in the last year.	1 day
Secondary	Patient satisfaction: Bauer Satisfaction Questionnaire	Difference in patients satisfaction about the surgery between patients who received a premedication and patients without premedication, measured with the Bauer Satisfaction Questionnaire (Reference 1) on the first postoperative day (visit 3). Patients rate their satisfaction regarding the first ten questions on a 3 point likert scale, regarding the questions #11 to 15 on a 4 point likert scale and the last question #16 is a yes/no question.	From intervention up to the 1st postoperative day (visit 3).
Secondary	Cognitive recovery	Difference in cognitive recovery (defined as difference between baseline assessment and assessment on the first postoperative day) between the two study-groups, measured by the Mini-cog .	Pre-interventional at baseline visit (visit 0) up to the 1st postoperative day (visit 3).
Secondary	Early postoperative delirium	Difference in the number of people with a new diagnosed early postoperative delirium between the two study groups, measured with the Confusion Assessment Method (CAM). There will be two assessments (visit 0 and 3).	Pre-interventional at baseline visit (visit 0) up to the 1st postoperative day (visit 3).
Secondary	Perioperative change of sleeping quality: Numeric Rating Scale	Difference in the change of the perioperative sleeping quality between the two different study groups, measured with the Numeric Rating Scale (numbers from 0-10) at baseline (visit 0), surgery day pre-operative (visit 1) and first postoperative day (visit 3).	Pre-interventional at baseline visit (visit 0) up to the 1st postoperative day (visit 3).
Secondary	Perioperative change of pain: Numeric Rating Scale	Difference in the change of pain between the two different study groups, measured with the Numeric Rating Scale (numbers from 0-10) at baseline (visit 0), surgery day pre-operative (visit 1), surgery day post-operative (visit 2) and first postoperative day (visit 3).	Pre-interventional at baseline visit (visit 0) up to the 1st postoperative day (visit 3).
Secondary	Perioperative change of well-being	Difference in the change of the perioperative well-being between the different two study groups, measured with the Numeric Rating Scale (numbers from 0-10) at baseline (visit 0) and first postoperative day (visit 3).	Pre-interventional at baseline visit (visit 0) up to the 1st postoperative day (visit 3).
Secondary	Patient cooperation directly preoperatively	Difference in the patient cooperation directly preoperative between the two different study groups, measured with the Numeric Rating Scale (numbers from 0-10).	On the day on surgery (1 day)
Secondary	Patients with rescue-midazolam application before anaesthesia induction	Difference in the number of patients who require "rescue-midazolam" application (additional midazolam) before anaesthesia induction between the two study groups.	On the day on surgery (1 day)
Secondary	Time to extubation	Difference in the needed time to extubation between the two study groups, measured after cessation of the hypnotic agent till removal of endotracheal tube or laryngeal mask airway.	At the end of surgery after cessation of the hypnotic agent until extubation (1 day)
Secondary	Change in the health-related quality of life assessment: European Quality of Life 5 Dimensions 3 Level questionnaire (EQ-5D-5L)	Difference in the change of the health-related quality of life between the two study-groups, measured with the European Quality of Life 5 Dimensions 3 Level questionnaire (EQ-5D-5L). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions. The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'Best imaginable health state' and 'Worst imaginable health state'. For analysis, please refer to the website of the test (please see reference 2)	Pre-interventional at baseline visit (visit 0) up to the 30th day (visit 4) after intervention
Secondary	Longer-term combined outcome of mortality or the new-onset of serious cardiac or pulmonary complications, or acute stroke, or acute kidney	Difference in the rate of mortality or the new-onset of serious cardiac or pulmonary complications, or acute stroke, or acute kidney injury between the two different study groups, assessed by interview and review of the medical history.	30 days after intervention (visit 4)
Secondary	Predefined complications	Difference in the number of predefined complications on the surgery day according to the medical charts between the two different study groups.	Surgery day (1 day)
Secondary	Hospital length of stay (LOS)	Difference in the hospital length of stay (LOS) between the two different study groups.	30 days after intervention (visit 4)
Secondary	Intensive care unit length of stay (ICU)-LOS	Difference in the intensive care unit (ICU)-LOS between the two different study groups.	30 days after intervention (visit 4)
Secondary	Patient's functional status of independency	Difference in the functional recovery between the two study groups, assessed by interview of the patient according to the National Surgical Quality Improvement Program (NSQIP). The questions contain the classification into independent, partially dependent, and totally dependent.	From the baseline visit (visit 0) to the 30th postoperative day (visit 4).